Kolexia
Macro Margaret Hématologie
Macro Margaret
Hématologie
Hôpital Côte de Nacre
Caen, France
230 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Lymphomes Maladie résiduelle Leucémies Translocation génétique Récidive tumorale locale Aberrations des chromosomes Amyloïdose

Collaborateurs

Voir plus
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Janssen
18 collaboration(s)
Dernière en 2023
Sanofi
8 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
4 collaboration(s)
Dernière en 2022
Celgene
3 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Essai Clinique (BMS)   20 mars 2024
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and IFM.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases   01 mars 2024
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma.
Blood   23 février 2024
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future oncology (London, England)   10 janvier 2024
Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
Thrombosis research   02 décembre 2023
Webconférences 03: Bien vivre au quotidien avec un myélome replay du 30 novembre 2023
Youtube @ AF3M   30 novembre 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
65th ASH Annual Meeting Abstracts   02 novembre 2023
Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies
65th ASH Annual Meeting Abstracts   02 novembre 2023